Clinical Trial Update: Effect And Safety Of Ziprasidone Compared To Other Atypical Antipsychotic Drug In Schizophrenic Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ziprasidone to other atypical antipsychotics in schizophrenia and schizoaffective disorder completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Ziprasidone (ziprasidone)

Snippet

Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 3 | Status: COMPLETED